Do you want to read an article? Please log in or register.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer